Daiichi Sankyo Co Limited Sponsored Adr News, Daiichi Sankyo Co Limited Sponsored Adr Quote, DSNKY Quote

Daiichi Sankyo Co Limited Sponsored Adr (OP:DSNKY) Delayed: 17.87 +0.45 (2.58%)

Prev. Close

$17.42

Today 6M 1Y 5Y

Open

$17.80

52 Wk High

$26.24

52 Wk Low

$18.86

Day High

$18.02

Day Low

$17.62

P/E

N/A

EPS

$0.00

Volume

115,648

Friends, Peers and Foes (?): 4568:JP, AZN, MRK, CGEN, CW9 (more...)

ALERTS | RSS

Jul 24, 2026 07:00 AM EU panel backs Enhertu plus pertuzumab for HER2+ breast cancer
Jul 24, 2026 07:00 AM Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer
Jun 29, 2026 02:30 AM Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors
Jun 26, 2026 07:01 AM EU panel backs Datroway for metastatic breast cancer patients
Jun 26, 2026 07:00 AM Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy
Jun 16, 2026 07:12 AM Daiichi Sankyo Company, Limited (4568:JP) (DSNKY) PT Lowered to JPY4,000 at Nomura/Instinet
Jun 16, 2026 12:22 AM Goldman Sachs Reiterates Buy Rating on Daiichi Sankyo Company, Limited (4568:JP) (DSNKY)
Jun 3, 2026 09:24 AM JPMorgan Downgrades Daiichi Sankyo Company, Limited (4568:JP) (DSNKY) to Neutral
May 28, 2026 07:00 AM Daiichi Sankyo Showcases Progress Across Industry-Leading Oncology Portfolio with Latest Research Updates at ASCO
May 26, 2026 11:00 AM Daiichi Sankyo Europe Reaffirms Commitment to Patient-Centred Care with Extensive Data Showcase at EAS Congress 2026

Entities mentioned with DSNKY

View All Entities